Navigation Links
InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
Date:11/7/2008

- Innovative Biotech Targets Another Large Well-Known Product and Continues

Expansion of Antibody Therapeutics Pipeline -

BRITISH COLUMBIA, Canada, Nov. 7 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX Venture: IXS; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces the development of a new antibody product from its DXL(TM) platform technology, DXL1218 (EGFR), for the prospective treatment of colorectal cancer.

"Recent experimental data suggests that DXL1218 (EGFR) is superior to competing commercialized products on the market, such as ERBITUX(R) (cetuximab), in terms of potency and efficacy," said Jeff Morhet, CEO and Chairman of InNexus. "I am very excited, as this latest development lends further support to the robustness and predictability of the DXL(TM) platform and the superiority of products from the platform over presently commercialized offerings."

Speaking on InNexus' announcement, Pablo Legorreta, Chief Executive Officer of Royalty Pharma said, "We are quite pleased with the rapid progress of our research partner InNexus. Jeff has had a vision for rapid product development based on DXL(TM) technology coupled with advanced in vivo studies and a significant regulatory strategy. We look forward to their continued rollout of products and performance."

Private Placement

InNexus also announces it intends to issue 10% unsecured convertible debentures, for maximum proceeds to InNexus of $1.25 million. Each debenture will be convertible into common shares of InNexus at the rate of one common share for each $0.10 of debt converted. The debenture will have a term of 2 years and net proceeds from the private placement will be used by InNexus for research and development and general corporate business. Closing of the private placement is expected to occur on or about 14 November 2008.

In connection with the private placement, certain insiders of InNexus comprised of some members of the Board and senior management, are expected to participate in the offering for an aggregate of approximately 40% on the same terms and InNexus may pay finders' fees to registered persons in an amount equal to 7% of the proceeds from the sale of the debentures to purchasers referred by such finder in accordance with the policies of the TSX Venture Exchange.

Participation in the private placement by insiders of InNexus is considered to be a related-party transaction as defined under Multilateral Instrument 61-101, however, the transaction is exempt from the formal valuation and minority shareholder approval requirements under the instrument as neither the fair market value of the securities being issued nor the consideration paid exceeds 25 per cent of InNexus' market capitalization.

Upon conversion of the debenture, the common shares will be subject to a four-month "hold period" from the date of conversion under the policies of the TSX Venture Exchange and applicable securities legislation.

About Colorectal Cancer

Colorectal cancer is the third most common cancer found in men and women in the United States and is a term referring to cancer that develops in the colon or rectum. The American Cancer Society estimates that there will be about 108,070 new cases of colon cancer and 40,740 new cases of rectal cancer in 2008 in the United States. Combined, they will cause about 49,960 deaths.

One of the leading products available is ERBITUX(R) (cetuximab) marketed by ImClone Systems Incorporated. ImClone recently reported that global net sales of ERBITUX(R) for the first quarter of 2008 grew to $417.3 million, an increase of 12% compared to $371.0 million for the previous quarter and an increase of 36% compared to $306.1 million for the same period last year.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.


'/>"/>
SOURCE InNexus Biotechnology Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InNexus Biotechnology Receives Patent Grants in Europe
2. InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum
3. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
4. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
5. InNexus Biotechnology Strengthens Patent Team With New Leadership
6. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
7. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
8. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
9. TechConnect World 2009 Matches Tomorrows Technology Solutions with Todays Business Needs for Clean-Technology, Biotechnology and Nanotechnology
10. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
11. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):